Myocardial Infarction in Heart Failure With Preserved Ejection Fraction: Pooled Analysis of 3 Clinical Trials.

[1]  Marc A Pfeffer,et al.  Heart Failure With Preserved Ejection Fraction In Perspective. , 2019, Circulation research.

[2]  Suzanne G. Orchard,et al.  Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly , 2018, The New England journal of medicine.

[3]  J. Cleland,et al.  Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease , 2018, The New England journal of medicine.

[4]  Akshay S. Desai,et al.  Sudden Death in Heart Failure With Preserved Ejection Fraction: A Competing Risks Analysis From the TOPCAT Trial. , 2018, JACC. Heart failure.

[5]  L. Lund,et al.  Significance of Ischemic Heart Disease in Patients With Heart Failure and Preserved, Midrange, and Reduced Ejection Fraction: A Nationwide Cohort Study , 2017, Circulation. Heart failure.

[6]  Sanjiv J. Shah,et al.  Mode of Death in Heart Failure With Preserved Ejection Fraction. , 2017, Journal of the American College of Cardiology.

[7]  D. Kass,et al.  Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap , 2016, Circulation.

[8]  M. Vaduganathan,et al.  Spectrum of epidemiological and clinical findings in patients with heart failure with preserved ejection fraction stratified by study design: a systematic review , 2016, European journal of heart failure.

[9]  Akshay S. Desai,et al.  Mortality following a cardiovascular or renal event in patients with type 2 diabetes in the ALTITUDE trial. , 2015, European heart journal.

[10]  R. McKelvie,et al.  Clinical Characteristics and Outcomes of Patients With Coronary Artery Disease and AnginaCLINICAL PERSPECTIVE , 2015 .

[11]  R. McKelvie,et al.  Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction , 2015, European journal of heart failure.

[12]  Akshay S. Desai,et al.  Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial , 2015, Circulation.

[13]  R. McKelvie,et al.  A prediction model for sudden cardiac death in patients with heart failure and preserved ejection fraction , 2014, European journal of heart failure.

[14]  Sanjiv J Shah,et al.  Spironolactone for heart failure with preserved ejection fraction. , 2014, The New England journal of medicine.

[15]  R. Vasan,et al.  Epidemiology and clinical course of heart failure with preserved ejection fraction , 2011, European journal of heart failure.

[16]  R. McKelvie,et al.  Mode of Death in Patients With Heart Failure and a Preserved Ejection Fraction: Results From the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) Trial , 2010, Circulation.

[17]  Daniel Levy,et al.  Relation of Disease Pathogenesis and Risk Factors to Heart Failure With Preserved or Reduced Ejection Fraction: Insights From the Framingham Heart Study of the National Heart, Lung, and Blood Institute , 2009, Circulation.

[18]  S. Solomon,et al.  Impact of hospitalization for acute coronary events on subsequent mortality in patients with chronic heart failure. , 2008, European heart journal.

[19]  Susan Anderson,et al.  Irbesartan in patients with heart failure and preserved ejection fraction. , 2008, The New England journal of medicine.

[20]  P. Libby,et al.  Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. , 2008, The New England journal of medicine.

[21]  Gissi-Hf Investigators.  Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial , 2008, The Lancet.

[22]  S. Solomon,et al.  Predictors of the first heart failure hospitalization in patients who are stable survivors of myocardial infarction complicated by pulmonary congestion and/or left ventricular dysfunction: a VALIANT study. , 2008, European heart journal.

[23]  Z. Massy,et al.  Prognosis of heart failure with preserved ejection fraction: a 5 year prospective population-based study. , 2008, European heart journal.

[24]  A. Jánosi,et al.  Rosuvastatin in older patients with systolic heart failure. , 2007, The New England journal of medicine.

[25]  D. Berman,et al.  Optimal medical therapy with or without PCI for stable coronary disease. , 2007, The New England journal of medicine.

[26]  S. Solomon,et al.  Effect of Candesartan on Cause-Specific Mortality in Heart Failure Patients: The Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) Program , 2004, Circulation.

[27]  Karl Swedberg,et al.  Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial , 2003, The Lancet.

[28]  Zhiliang Ying,et al.  Semiparametric regression for the mean and rate functions of recurrent events , 2000 .

[29]  S. Yusuf,et al.  Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. , 1992, The New England journal of medicine.